Cancer‐associated fibroblasts mediate resistance to neoadjuvant therapy in breast cancer.

This article explores the impact of cancer-associated fibroblasts (CAFs) on the effectiveness of neoadjuvant chemotherapy (NAC) in breast cancer patients. The study reveals that a chemo-resistant stroma (CRS) signature is linked to poorer outcomes and lower survival rates in breast cancer patients. Furthermore, the research demonstrates that CAFs play a significant role in NAC resistance and cancer progression. The findings emphasize the importance of considering the tumor microenvironment when predicting NAC response and developing effective treatment strategies. The study also suggests that targeting CAFs and their senescent state could be a promising approach to overcoming NAC resistance. [Extracted from the article]